[{"id":"067f213e-03a5-45b6-8ae7-e5474fb8a9c9","acronym":"C-906289-002","url":"https://clinicaltrials.gov/study/NCT05308264","created_at":"2025-02-25T20:13:27.067Z","updated_at":"2025-02-25T20:13:27.067Z","phase":"Phase 1/2","brief_title":"Study of R289 in Participants With Lower-risk Myelodysplastic Syndromes (LR MDS)","source_id_and_acronym":"NCT05308264 - C-906289-002","lead_sponsor":"Rigel Pharmaceuticals","biomarkers":" TNFA • CRP","pipe":" | ","alterations":" Chr del(5q)","tags":["TNFA • CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(5q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e R289"],"overall_status":"Recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 09/12/2022","start_date":" 09/12/2022","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2025-01-16"},{"id":"d2fff3d6-ffea-4d7d-80f3-4801459b6711","acronym":"","url":"https://clinicaltrials.gov/study/NCT04659616","created_at":"2021-01-19T20:42:17.932Z","updated_at":"2024-07-02T16:35:10.819Z","phase":"Phase 1","brief_title":"Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia","source_id_and_acronym":"NCT04659616","lead_sponsor":"OHSU Knight Cancer Institute","biomarkers":" TP53 • FLT3 • ABL1 • BCR • EZH2 • RUNX1 • SF3B1 • ASXL1 • KMT2A • SRSF2 • BCOR • U2AF1 • STAG2 • MECOM • NUP214 • GATA2 • MLLT3 • CDKN1A • DEK • ZRSR2","pipe":" | ","alterations":" TP53 mutation • FLT3 mutation • RUNX1 mutation • ASXL1 mutation • EZH2 mutation • MLL rearrangement • SRSF2 mutation • U2AF1 mutation • BCOR mutation • Chr del(5q) • STAG2 mutation • FLT3 wild-type • Chr t(9;11) • ZRSR2 mutation","tags":["TP53 • FLT3 • ABL1 • BCR • EZH2 • RUNX1 • SF3B1 • ASXL1 • KMT2A • SRSF2 • BCOR • U2AF1 • STAG2 • MECOM • NUP214 • GATA2 • MLLT3 • CDKN1A • DEK • ZRSR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • FLT3 mutation • RUNX1 mutation • ASXL1 mutation • EZH2 mutation • MLL rearrangement • SRSF2 mutation • U2AF1 mutation • BCOR mutation • Chr del(5q) • STAG2 mutation • FLT3 wild-type • Chr t(9;11) • ZRSR2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Pemazyre (pemigatinib) • daunorubicin • Starasid (cytarabine ocfosfate)"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 01/14/2021","start_date":" 01/14/2021","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-04-09"},{"id":"cb11cd54-0bac-4f20-bf14-95c5e18524bf","acronym":"","url":"https://clinicaltrials.gov/study/NCT04187703","created_at":"2022-04-24T09:01:41.679Z","updated_at":"2024-07-02T16:35:15.464Z","phase":"Phase 1","brief_title":"5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies","source_id_and_acronym":"NCT04187703","lead_sponsor":"Benjamin Tomlinson","biomarkers":" ABL1 • BCR • CD14 • DCK • DNMT1 • ITGAM • NT5C","pipe":" | ","alterations":" Chr del(5q)","tags":["ABL1 • BCR • CD14 • DCK • DNMT1 • ITGAM • NT5C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(5q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • decitabine"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 11/16/2020","start_date":" 11/16/2020","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-03-11"},{"id":"b62639b3-3bfc-4f4f-81ac-2892933d901a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05115630","created_at":"2021-11-10T14:13:02.708Z","updated_at":"2024-07-02T16:35:19.132Z","phase":"Phase 1/2","brief_title":"Off-the-shelf NK Cells + SCT for Myeloid Malignancies","source_id_and_acronym":"NCT05115630","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • FLT3 • ABL1 • BCR • NPM1 • RUNX1 • ASXL1 • KMT2A • MECOM • NUP214 • GATA2 • DEK","pipe":" | ","alterations":" TP53 mutation • FLT3 mutation • RUNX1 mutation • ASXL1 mutation • MLL rearrangement • Chr del(5q) • FLT3 wild-type","tags":["TP53 • FLT3 • ABL1 • BCR • NPM1 • RUNX1 • ASXL1 • KMT2A • MECOM • NUP214 • GATA2 • DEK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • FLT3 mutation • RUNX1 mutation • ASXL1 mutation • MLL rearrangement • Chr del(5q) • FLT3 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • melphalan • fludarabine IV • mesna • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 04/08/2022","start_date":" 04/08/2022","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2024-02-16"},{"id":"58702155-c7f5-4adb-9515-8aecf200fa86","acronym":"","url":"https://clinicaltrials.gov/study/NCT04620681","created_at":"2021-01-19T20:34:25.590Z","updated_at":"2024-07-02T16:35:20.265Z","phase":"Phase 1/2","brief_title":"CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AML","source_id_and_acronym":"NCT04620681","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" JAK2 • RUNX1 • SF3B1 • ASXL1 • TET2 • SRSF2 • BCOR • U2AF1 • STAG2 • CALR • CDKN1A • ZRSR2","pipe":" | ","alterations":" TP53 mutation • Chr del(11q) • U2AF1 mutation • Chr del(5q) • Chr del(7q)","tags":["JAK2 • RUNX1 • SF3B1 • ASXL1 • TET2 • SRSF2 • BCOR • U2AF1 • STAG2 • CALR • CDKN1A • ZRSR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr del(11q) • U2AF1 mutation • Chr del(5q) • Chr del(7q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 19","initiation":"Initiation: 01/14/2021","start_date":" 01/14/2021","primary_txt":" Primary completion: 08/10/2024","primary_completion_date":" 08/10/2024","study_txt":" Completion: 08/10/2024","study_completion_date":" 08/10/2024","last_update_posted":"2024-02-08"},{"id":"0f841029-f2ce-4cb1-849c-75709569b46f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03613532","created_at":"2021-03-05T16:52:31.672Z","updated_at":"2024-07-02T16:35:22.047Z","phase":"Phase 1","brief_title":"Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN","source_id_and_acronym":"NCT03613532","lead_sponsor":"Jacqueline Garcia, MD","biomarkers":" KRAS • TP53 • FLT3 • ABL1 • NRAS • BCR • BCL2 • NPM1 • NF1 • RUNX1 • SF3B1 • ASXL1 • KMT2A • PTPN11 • SRSF2 • BCOR • U2AF1 • STAG2 • MECOM • NUP214 • GATA2 • DEK • RIT1 • ZRSR2","pipe":" | ","alterations":" TP53 mutation • KRAS mutation • NRAS mutation • RUNX1 mutation • RAS mutation • ASXL1 mutation • CBL mutation • MLL rearrangement • U2AF1 mutation • Chr del(5q) • FLT3 wild-type","tags":["KRAS • TP53 • FLT3 • ABL1 • NRAS • BCR • BCL2 • NPM1 • NF1 • RUNX1 • SF3B1 • ASXL1 • KMT2A • PTPN11 • SRSF2 • BCOR • U2AF1 • STAG2 • MECOM • NUP214 • GATA2 • DEK • RIT1 • ZRSR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • KRAS mutation • NRAS mutation • RUNX1 mutation • RAS mutation • ASXL1 mutation • CBL mutation • MLL rearrangement • U2AF1 mutation • Chr del(5q) • FLT3 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • Inqovi (decitabine/cedazuridine) • fludarabine IV • busulfan"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 10/24/2018","start_date":" 10/24/2018","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-01-26"},{"id":"738fa48d-f8a9-4706-a089-656371dd06cc","acronym":"","url":"https://clinicaltrials.gov/study/NCT01063647","created_at":"2021-01-18T04:11:24.649Z","updated_at":"2024-07-02T16:35:30.505Z","phase":"Phase 2","brief_title":"Dose-range Finding Treosulfan-based Conditioning","source_id_and_acronym":"NCT01063647","lead_sponsor":"medac GmbH","biomarkers":" ABL1 • BCR • HLA-DRB1","pipe":" | ","alterations":" Chr del(5q)","tags":["ABL1 • BCR • HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(5q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Grafapex (treosulfan)"],"overall_status":"Completed","enrollment":" Enrollment 56","initiation":"Initiation: 11/01/2001","start_date":" 11/01/2001","primary_txt":" Primary completion: 06/01/2005","primary_completion_date":" 06/01/2005","study_txt":" Completion: 06/01/2006","study_completion_date":" 06/01/2006","last_update_posted":"2023-11-03"},{"id":"7d36623f-54df-47be-a4e4-1dee851f8906","acronym":"COALA","url":"https://clinicaltrials.gov/study/NCT05499611","created_at":"2022-11-08T19:21:31.726Z","updated_at":"2024-07-02T16:35:31.379Z","phase":"","brief_title":"Impact of Optical Genome Mapping in Acute Myeloblastic Leukemia","source_id_and_acronym":"NCT05499611 - COALA","lead_sponsor":"University Hospital, Bordeaux","biomarkers":" TP53 • NPM1 • RUNX1 • ASXL1 • CEBPA","pipe":" | ","alterations":" Chr del(5q) • Chr t(9;11)","tags":["TP53 • NPM1 • RUNX1 • ASXL1 • CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(5q) • Chr t(9;11)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 01/27/2023","start_date":" 01/27/2023","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 01/01/2024","study_completion_date":" 01/01/2024","last_update_posted":"2023-10-27"},{"id":"f998438e-b773-4345-93ac-9c264d1adecf","acronym":"","url":"https://clinicaltrials.gov/study/NCT02646839","created_at":"2021-01-18T12:52:48.002Z","updated_at":"2024-07-02T16:35:31.543Z","phase":"Phase 2","brief_title":"KIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL/AML/MDS Allo-HCT Children","source_id_and_acronym":"NCT02646839","lead_sponsor":"Michael Pulsipher, MD","biomarkers":" ABL1 • BCR • KIR2DL1","pipe":" | ","alterations":" Chr del(5q)","tags":["ABL1 • BCR • KIR2DL1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(5q)"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 50","initiation":"Initiation: 10/01/2015","start_date":" 10/01/2015","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 08/01/2024","study_completion_date":" 08/01/2024","last_update_posted":"2023-10-26"},{"id":"eecc0761-d3fa-49cf-82cd-389c0096a5df","acronym":"LUSPLUS","url":"https://clinicaltrials.gov/study/NCT05181592","created_at":"2022-01-06T22:53:42.390Z","updated_at":"2025-02-25T14:16:35.136Z","phase":"Phase 3","brief_title":"Assessment of Effectiveness and Safety of Luspatercept in Patients Suffering From Lower-risk Myelodysplastic Syndrome.","source_id_and_acronym":"NCT05181592 - LUSPLUS","lead_sponsor":"GWT-TUD GmbH","biomarkers":" SF3B1","pipe":" | ","alterations":" SF3B1 mutation • Chr del(5q)","tags":["SF3B1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SF3B1 mutation • Chr del(5q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Reblozyl (luspatercept-aamt)"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 10/27/2021","start_date":" 10/27/2021","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2023-10-12"},{"id":"0d3ee8f5-d80e-4d1b-9490-6b52ff00aad7","acronym":"","url":"https://clinicaltrials.gov/study/NCT00816413","created_at":"2021-07-05T16:06:13.151Z","updated_at":"2024-07-02T16:35:40.198Z","phase":"Phase 1/2","brief_title":"Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer","source_id_and_acronym":"NCT00816413","lead_sponsor":"University of Nebraska","biomarkers":" HLA-B • HLA-C","pipe":" | ","alterations":" Chr del(5q) • Chr del(7q)","tags":["HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(5q) • Chr del(7q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclosporin A microemulsion • pentostatin • cyclosporine • ondansetron intravenous"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/01/2008","start_date":" 09/01/2008","primary_txt":" Primary completion: 02/01/2010","primary_completion_date":" 02/01/2010","study_txt":" Completion: 02/01/2010","study_completion_date":" 02/01/2010","last_update_posted":"2023-08-14"},{"id":"95a652b1-308b-4dec-885c-a10583b02377","acronym":"","url":"https://clinicaltrials.gov/study/NCT01743131","created_at":"2021-01-18T07:37:32.437Z","updated_at":"2024-07-02T16:35:49.415Z","phase":"Phase 2","brief_title":"Abatacept as GVHD Prophylaxis Phase 2","source_id_and_acronym":"NCT01743131","lead_sponsor":"Boston Children's Hospital","biomarkers":" ABL1 • BCR • HLA-DRB1 • CD4","pipe":" | ","alterations":" Chr del(5q)","tags":["ABL1 • BCR • HLA-DRB1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(5q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Orencia (abatacept)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 186","initiation":"Initiation: 02/01/2013","start_date":" 02/01/2013","primary_txt":" Primary completion: 06/01/2018","primary_completion_date":" 06/01/2018","study_txt":" Completion: 09/01/2023","study_completion_date":" 09/01/2023","last_update_posted":"2023-04-27"},{"id":"f69db2be-05a6-45ef-a79d-7dae6afc1775","acronym":"","url":"https://clinicaltrials.gov/study/NCT01760655","created_at":"2021-01-18T07:44:19.143Z","updated_at":"2024-07-02T16:35:58.053Z","phase":"Phase 2","brief_title":"Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies","source_id_and_acronym":"NCT01760655","lead_sponsor":"Sidney Kimmel Cancer Center at Thomas Jefferson University","biomarkers":" TP53 • FLT3","pipe":" | ","alterations":" TP53 deletion • Chr del(5q) • Chr del(7q)","tags":["TP53 • FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 deletion • Chr del(5q) • Chr del(7q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • thiotepa • busulfan • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 62","initiation":"Initiation: 12/24/2012","start_date":" 12/24/2012","primary_txt":" Primary completion: 04/15/2022","primary_completion_date":" 04/15/2022","study_txt":" Completion: 12/05/2022","study_completion_date":" 12/05/2022","last_update_posted":"2023-01-06"},{"id":"75324f35-f2d9-4dfd-9fdb-c9e85bdeb377","acronym":"","url":"https://clinicaltrials.gov/study/NCT00075803","created_at":"2021-01-18T00:12:11.274Z","updated_at":"2024-07-02T16:35:58.208Z","phase":"Phase 3","brief_title":"Comparison of Fluconazole vs Voriconazole to Treat Fungal Infections for Blood and Marrow Transplants (BMT CTN 0101)","source_id_and_acronym":"NCT00075803","lead_sponsor":"Medical College of Wisconsin","biomarkers":" HLA-DRB1 • HLA-B","pipe":" | ","alterations":" Chr del(5q)","tags":["HLA-DRB1 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(5q)"],"overall_status":"Completed","enrollment":" Enrollment 600","initiation":"Initiation: 11/01/2003","start_date":" 11/01/2003","primary_txt":" Primary completion: 09/01/2006","primary_completion_date":" 09/01/2006","study_txt":" Completion: 09/01/2007","study_completion_date":" 09/01/2007","last_update_posted":"2023-01-04"},{"id":"7768c77e-c7df-4a92-91ad-6751d0d3d024","acronym":"BMT CTN 0201","url":"https://clinicaltrials.gov/study/NCT00075816","created_at":"2021-01-18T00:12:11.695Z","updated_at":"2024-07-02T16:35:58.204Z","phase":"Phase 3","brief_title":"Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201)","source_id_and_acronym":"NCT00075816 - BMT CTN 0201","lead_sponsor":"Medical College of Wisconsin","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":" | ","alterations":" Chr del(5q)","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(5q)"],"overall_status":"Completed","enrollment":" Enrollment 551","initiation":"Initiation: 01/01/2004","start_date":" 01/01/2004","primary_txt":" Primary completion: 04/01/2013","primary_completion_date":" 04/01/2013","study_txt":" Completion: 04/01/2014","study_completion_date":" 04/01/2014","last_update_posted":"2023-01-04"},{"id":"c0aae5a2-d214-4204-8770-3603ac0b210b","acronym":"MCC-18973","url":"https://clinicaltrials.gov/study/NCT03072043","created_at":"2021-01-18T15:08:04.521Z","updated_at":"2024-07-02T16:36:18.077Z","phase":"Phase 1b/2","brief_title":"Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms","source_id_and_acronym":"NCT03072043 - MCC-18973","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation • Chr del(5q)","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr del(5q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • eprenetapopt (APR-246)"],"overall_status":"Completed","enrollment":" Enrollment 55","initiation":"Initiation: 05/18/2017","start_date":" 05/18/2017","primary_txt":" Primary completion: 11/15/2019","primary_completion_date":" 11/15/2019","study_txt":" Completion: 12/08/2021","study_completion_date":" 12/08/2021","last_update_posted":"2022-01-24"},{"id":"c9acec8c-0e67-476c-9285-256811a2ef31","acronym":"","url":"https://clinicaltrials.gov/study/NCT02046122","created_at":"2021-01-18T09:23:57.683Z","updated_at":"2024-07-02T16:36:37.907Z","phase":"Phase 1/2","brief_title":"Adoptive Transfer of Haplo-identical DLI for AML and MDS","source_id_and_acronym":"NCT02046122","lead_sponsor":"Duke University","biomarkers":" FLT3","pipe":" | ","alterations":" Chr del(5q)","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(5q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • idarubicin hydrochloride"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 07/01/2014","start_date":" 07/01/2014","primary_txt":" Primary completion: 06/15/2017","primary_completion_date":" 06/15/2017","study_txt":" Completion: 07/31/2019","study_completion_date":" 07/31/2019","last_update_posted":"2020-12-03"},{"id":"837927b2-eb6b-4652-92eb-3c2283ccc219","acronym":"","url":"https://clinicaltrials.gov/study/NCT02487459","created_at":"2021-01-18T11:58:41.219Z","updated_at":"2024-07-02T16:36:40.421Z","phase":"Phase 1/2","brief_title":"Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies","source_id_and_acronym":"NCT02487459","lead_sponsor":"Bellicum Pharmaceuticals","biomarkers":" FLT3 • KMT2A • HLA-DRB1 • HLA-B","pipe":" | ","alterations":" FLT3 mutation • MLL rearrangement • Chr del(5q) • Chr del(7q)","tags":["FLT3 • KMT2A • HLA-DRB1 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • MLL rearrangement • Chr del(5q) • Chr del(7q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CaspaCIDe DLI (rimiducid activated rivogenlecleucel) • rimiducid (AP1903)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 07/01/2016","start_date":" 07/01/2016","primary_txt":" Primary completion: 06/01/2017","primary_completion_date":" 06/01/2017","study_txt":" Completion: 06/01/2017","study_completion_date":" 06/01/2017","last_update_posted":"2020-10-05"},{"id":"74794339-c95b-4f68-b9e4-6e7534b0237e","acronym":"","url":"https://clinicaltrials.gov/study/NCT01010217","created_at":"2021-01-18T03:57:19.800Z","updated_at":"2024-07-02T16:36:47.655Z","phase":"Phase 2","brief_title":"Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide","source_id_and_acronym":"NCT01010217","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" FLT3 • KMT2A","pipe":" | ","alterations":" FLT3 mutation • MLL rearrangement • Chr del(5q) • Chr del(7q)","tags":["FLT3 • KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • MLL rearrangement • Chr del(5q) • Chr del(7q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • melphalan • fludarabine IV • mesna • thiotepa • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 176","initiation":"Initiation: 11/05/2009","start_date":" 11/05/2009","primary_txt":" Primary completion: 10/05/2017","primary_completion_date":" 10/05/2017","study_txt":" Completion: 10/05/2017","study_completion_date":" 10/05/2017","last_update_posted":"2020-03-25"},{"id":"c16de0cf-b9fe-4442-8cd2-246fe6771da8","acronym":"","url":"https://clinicaltrials.gov/study/NCT01287104","created_at":"2021-01-18T05:13:27.987Z","updated_at":"2024-07-02T16:36:56.638Z","phase":"Phase 1","brief_title":"A Phase I Study of NK Cell Infusion Following Allogeneic Peripheral Blood Stem Cell Transplantation From Related or Matched Unrelated Donors in Pediatric Patients With Solid Tumors and Leukemias","source_id_and_acronym":"NCT01287104","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" FLT3 • NPM1 • CEBPA • CD4 • IL15 • IL7 • KIR2DS2","pipe":" | ","alterations":" FLT3-ITD mutation • NPM1 mutation • CEBPA mutation • Chr del(5q)","tags":["FLT3 • NPM1 • CEBPA • CD4 • IL15 • IL7 • KIR2DS2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • NPM1 mutation • CEBPA mutation • Chr del(5q)"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 01/29/2011","start_date":" 01/29/2011","primary_txt":" Primary completion: 06/28/2018","primary_completion_date":" 06/28/2018","study_txt":" Completion: 06/28/2018","study_completion_date":" 06/28/2018","last_update_posted":"2019-08-22"},{"id":"2c442f0a-f32d-4c0b-9e96-3b802adfd2fb","acronym":"S1203","url":"https://clinicaltrials.gov/study/NCT01802333","created_at":"2021-01-18T07:58:46.839Z","updated_at":"2024-07-02T16:37:04.598Z","phase":"Phase 3","brief_title":"Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia","source_id_and_acronym":"NCT01802333 - S1203","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" FLT3","pipe":" | ","alterations":" Chr del(5q)","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(5q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • daunorubicin • Zolinza (vorinostat) • idarubicin hydrochloride • Starasid (cytarabine ocfosfate)"],"overall_status":"Completed","enrollment":" Enrollment 754","initiation":"Initiation: 02/12/2013","start_date":" 02/12/2013","primary_txt":" Primary completion: 06/15/2017","primary_completion_date":" 06/15/2017","study_txt":" Completion: 06/15/2017","study_completion_date":" 06/15/2017","last_update_posted":"2018-12-19"},{"id":"480370cf-ef5e-4244-bb40-03c9bff296dc","acronym":"","url":"https://clinicaltrials.gov/study/NCT01385787","created_at":"2021-01-18T05:41:07.798Z","updated_at":"2024-07-02T16:37:18.110Z","phase":"","brief_title":"MRD Testing Before and After Hematopoietic Cell Transplantation for Pediatric Acute Myeloid Leukemia","source_id_and_acronym":"NCT01385787","lead_sponsor":"Center for International Blood and Marrow Transplant Research","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":" | ","alterations":" Chr del(5q)","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(5q)"],"overall_status":"Completed","enrollment":" Enrollment 150","initiation":"Initiation: 10/01/2011","start_date":" 10/01/2011","primary_txt":" Primary completion: 05/01/2017","primary_completion_date":" 05/01/2017","study_txt":" Completion: 05/01/2017","study_completion_date":" 05/01/2017","last_update_posted":"2017-09-07"},{"id":"db0a2604-60f8-4da8-9709-756a668e89e5","acronym":"","url":"https://clinicaltrials.gov/study/NCT01520558","created_at":"2021-01-18T06:23:46.768Z","updated_at":"2024-07-02T16:37:20.522Z","phase":"Phase 1/2","brief_title":"CNDO-109-AANK for AML in First Complete Remission (CR1)","source_id_and_acronym":"NCT01520558","lead_sponsor":"Coronado Biosciences, Inc.","biomarkers":" FLT3 • NPM1 • HLA-B","pipe":" | ","alterations":" FLT3 mutation • NPM1 mutation • Chr del(5q)","tags":["FLT3 • NPM1 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • NPM1 mutation • Chr del(5q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CNDO-109"],"overall_status":"Unknown status","enrollment":" Enrollment 12","initiation":"Initiation: 12/01/2012","start_date":" 12/01/2012","primary_txt":" Primary completion: 03/01/2016","primary_completion_date":" 03/01/2016","study_txt":" Completion: 02/01/2018","study_completion_date":" 02/01/2018","last_update_posted":"2017-06-29"},{"id":"ca926512-6064-4fa7-b79f-522281599998","acronym":"","url":"https://clinicaltrials.gov/study/NCT00049504","created_at":"2021-01-18T00:05:09.256Z","updated_at":"2024-07-02T16:37:22.043Z","phase":"Phase 2","brief_title":"Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer","source_id_and_acronym":"NCT00049504","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" CD8 • HLA-DRB1 • PTPRC • NCAM1 • HLA-B • HLA-C • NCR1","pipe":" | ","alterations":" CD8 expression • Chr del(5q) • CD4 expression","tags":["CD8 • HLA-DRB1 • PTPRC • NCAM1 • HLA-B • HLA-C • NCR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 expression • Chr del(5q) • CD4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 53","initiation":"Initiation: 01/01/2002","start_date":" 01/01/2002","primary_txt":" Primary completion: 03/01/2011","primary_completion_date":" 03/01/2011","study_txt":" Completion: 02/01/2014","study_completion_date":" 02/01/2014","last_update_posted":"2017-05-17"}]